American Life Science Pharmaceuticals, Inc., a San Diego, CA-based developer of a drug that prevents Alzheimer’s disease (AD), has received a $248,000 grant from The Alzheimer’s Drug Discovery Foundation.
The funds will allow the company to manufacture its lead drug candidate to be used in preclinical toxicology testing in preparation for entering Phase I clinical trials early in 2011. American Life Science Pharmaceuticals has identified a new class of drugs that prevent memory deficit and pathology in animal models of AD.
Michael D. Pierschbacher, PhD., company CEO, said: “Our proprietary lead compound, AB-007, has previously been evaluated for a different indication in human clinical trials and shown to be safe and well tolerated.
“Our goal is to conduct clinical trials on AB-007 to confirm as soon as possible the observed preclinical efficacy for treatment of AD”.
The company is currently launching its efforts to raise Series A financing.